Oncotarget

Research Papers:

Decreased expression of FOXF2 as new predictor of poor prognosis in stage I non-small cell lung cancer

Peng-Zhou Kong _, Guang-Ming Li, Yin Tian, Bin Song and RuYi Shi

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:55601-55610. https://doi.org/10.18632/oncotarget.10876

Metrics: PDF 1180 views  |   HTML 1593 views  |   ?  


Abstract

Peng-Zhou Kong1,2,*, Guang-Ming Li3,*, Yin Tian4,5, Bin Song1,6, RuYi Shi1,7

1Translational Medicine Research Center, Shanxi Medical University, Taiyuan 030001, China

2Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China

3School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China

4Department of General Surgery, The Second Hospital of JingZhou, JingZhou 434000, China

5Department of Biochemistry and Molecular Biology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

6Department of Oncology, The First Hospital, Shanxi Medical University, Taiyuan 030001, China

7Department of Cell Biology and Genetics, Shanxi Medical University, Taiyuan 030001, China

*Both authors have shared co-first authorship

Correspondence to:

Peng-Zhou Kong, email: kongpzh@163.com

Keywords: FOXF2, non-small-cell lung carcinoma, survival, clinical stage

Received: April 13, 2016     Accepted: July 10, 2016     Published: July 28, 2016

ABSTRACT

Background: Forkhead box F2 (FOXF2) is relatively limited to the adult lung, but its contribution to non-small cell lung cancer (NSCLC) prognosis is unclear.

Results: FOXF2 mRNA levels in NSCLC were lower than that in paired normal lung tissues (P = 0.012). The FOXF2low patients had shorter survival time than the FOXF2high patients (P = 0.024) especially in stage I (P = 0.002), chemotherapy (P = 0.018) and < 60 age groups (P = 0.002). Lower FOXF2 mRNA levels could independently predict poorer survival for patients with NSCLC (HR = 2.384, 95% CI = 1.241–4.577; P = 0.009), especially in stage I (HR =4.367, 95% CI =1.599–11.925; P = 0.004). The two independent datasets confirmed our findings.

Methods: We examined FOXF2 mRNA levels in 84 primary NSCLC and 8 normal lung tissues using qRT-PCR. Rank-sum tests and chi-square tests were used to assess the differences among groups with various clinicopathological factors. Kaplan-Meier tests were used to compare survival status in patients with different FOXF2 mRNA levels. Cox proportional hazards regression model was used to evaluate the predictive value of FOXF2 mRNA level in NSCLC patients. Independent validation was performed using an independent dataset (98 samples) and an online survival analysis software Kaplan-Meier plotter (1928 samples).

Conclusions: Our results demonstrated that decreased FOXF2 expression is an independent predictive factor for poor prognosis of patients with NSCLC, especially in stage I NSCLC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10876